Professor Jack Cuzick

CBE, PhD, FRS, FMedSci, FRCP (hon)
Director, Wolfson Institute of Preventive Medicine
Centre Lead, Research Theme Lead
Research Focus

I am the Director of Wolfson Institute of Preventive Medicine and also Head of Centre for Cancer Prevention. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.

Key Publications

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2015) 16(1):67-75. PMID: 25497694

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2014) 383(9922):1041-8. PMID: 24333009

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Onc (2011) 12(3):245-255. PMID: 21310658

A breast cancer prediction model incorporating familial and personal risk factors. Statist Med (2004) 23: 1111-1130. PMID: 15057881

Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 362: 1871-1876. PMID: 14667741

Major Funding
  • 2018-2023- CRUK, Catalyst, £1.4M
  • 2017-2020- Barts Charity, Preventative Neurology, £1.5M
  • 2014-2019- CRUK, Cancer Prevention, £6.9M
  • 2007-2019- CRUK, IBIS II, £2M
Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Research

I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.

I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.

Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Major Funding
  • 2018-2023- CRUK, Catalyst, £1.4M
  • 2017-2020- Barts Charity, Preventative Neurology, £1.5M
  • 2014-2019- CRUK, Cancer Prevention, £6.9M
  • 2007-2019- CRUK, IBIS II, £2M
Recent Publications

Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom) Renehan AG, Pegington M, Harvie MN et al. British Journal of Cancer (2020) 122(7) 1552-1561

A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density Brentnall AR, van Veen EM, Harkness EF et al. International Journal of Cancer (2020) 146(7) 2122-2129

10-year results of the International Breast Cancer Intervention Study II (IBIS-II) Cuzick J, Sestak I, Forbes JF et al. BREAST CANCER RESEARCH AND TREATMENT (2020) 180(11) 527-527
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000519166100027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

A genome-wide association study of vaginal discharge during tamoxifen therapy for breast cancer prevention Hale MJ, Cuzick J, Sestak I BREAST CANCER RESEARCH AND TREATMENT (2020) 180(11) 570-571
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000519166100128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

Correlations between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: a TransATAC study Buus R, Sestak I, Dowsett M et al. BREAST CANCER RESEARCH AND TREATMENT (2020) 180(11) 543-543
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000519166100061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk Dobson R, Jitlal M, Marshall CR et al. Annals of Neurology (2020) 87(7) 599-608

Prognostic value of EndoPredict and oncotype recurrence score according to patients' age Sestak I, Kronenwett R, Buus R et al. BREAST CANCER RESEARCH AND TREATMENT (2020) 180(11) 580-580
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000519166100152&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

Validation of the Clinical Treatment Score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study Sestak I, Crager M, Cuzick J et al. BREAST CANCER RESEARCH AND TREATMENT (2020) 180(11) 532-533
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000519166100037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. Cuzick J, Adcock R, Carozzi F et al. Int J Cancer (2020) (2)
https://www.ncbi.nlm.nih.gov/pubmed/32170961

Risk Models for Breast Cancer and Their Validation. Brentnall AR, Cuzick J Statistical Science: a review journal (2020) 35(1) 14-30
https://www.ncbi.nlm.nih.gov/pubmed/32226220

For additional publications, please click here
Biography

I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.

I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.

Upcoming Events
  1. MSc Surgical Programmes Online Open Event

    June 2 @ 2:00 pm - 4:00 pm
  2. The London Pancreas Workshop 2020

    September 11 @ 9:30 am - 4:30 pm
© 2013 ~ 2020 Cancer Research UK Barts Centre